288 related articles for article (PubMed ID: 25500831)
1. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
Kreisl WC; Bhatia R; Morse CL; Woock AE; Zoghbi SS; Shetty HU; Pike VW; Innis RB
J Nucl Med; 2015 Jan; 56(1):82-7. PubMed ID: 25500831
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.
Kreisl WC; Liow JS; Kimura N; Seneca N; Zoghbi SS; Morse CL; Herscovitch P; Pike VW; Innis RB
J Nucl Med; 2010 Apr; 51(4):559-66. PubMed ID: 20237038
[TBL] [Abstract][Full Text] [Related]
3. Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET.
Kannan P; Brimacombe KR; Kreisl WC; Liow JS; Zoghbi SS; Telu S; Zhang Y; Pike VW; Halldin C; Gottesman MM; Innis RB; Hall MD
Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2593-8. PubMed ID: 21262843
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys.
Liow JS; Kreisl W; Zoghbi SS; Lazarova N; Seneca N; Gladding RL; Taku A; Herscovitch P; Pike VW; Innis RB
J Nucl Med; 2009 Jan; 50(1):108-15. PubMed ID: 19091890
[TBL] [Abstract][Full Text] [Related]
5. Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
Damont A; Goutal S; Auvity S; Valette H; Kuhnast B; Saba W; Tournier N
Eur J Pharm Sci; 2016 Aug; 91():98-104. PubMed ID: 27283486
[TBL] [Abstract][Full Text] [Related]
6. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
[TBL] [Abstract][Full Text] [Related]
7. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.
Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O
J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428
[TBL] [Abstract][Full Text] [Related]
8. N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier.
Kannan P; Brimacombe KR; Zoghbi SS; Liow JS; Morse C; Taku AK; Pike VW; Halldin C; Innis RB; Gottesman MM; Hall MD
Drug Metab Dispos; 2010 Jun; 38(6):917-22. PubMed ID: 20212014
[TBL] [Abstract][Full Text] [Related]
9. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
[TBL] [Abstract][Full Text] [Related]
10. Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein.
Seneca N; Zoghbi SS; Liow JS; Kreisl W; Herscovitch P; Jenko K; Gladding RL; Taku A; Pike VW; Innis RB
J Nucl Med; 2009 May; 50(5):807-13. PubMed ID: 19372478
[TBL] [Abstract][Full Text] [Related]
11. 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux.
Zoghbi SS; Liow JS; Yasuno F; Hong J; Tuan E; Lazarova N; Gladding RL; Pike VW; Innis RB
J Nucl Med; 2008 Apr; 49(4):649-56. PubMed ID: 18344435
[TBL] [Abstract][Full Text] [Related]
12. Imaging P-glycoprotein function in rats using [(11)C]-N-desmethyl-loperamide.
Farwell MD; Chong DJ; Iida Y; Bae SA; Easwaramoorthy B; Ichise M
Ann Nucl Med; 2013 Aug; 27(7):618-24. PubMed ID: 23572210
[TBL] [Abstract][Full Text] [Related]
13. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
[TBL] [Abstract][Full Text] [Related]
14. Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein.
Kurnik D; Sofowora GG; Donahue JP; Nair UB; Wilkinson GR; Wood AJ; Muszkat M
Anesthesiology; 2008 Dec; 109(6):1092-9. PubMed ID: 19034106
[TBL] [Abstract][Full Text] [Related]
15. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
Biali ME; Auvity S; Cisternino S; Smirnova M; Hacker M; Zeitlinger M; Mairinger S; Tournier N; Bauer M; Langer O
Mol Pharm; 2023 Nov; 20(11):5877-5887. PubMed ID: 37883694
[TBL] [Abstract][Full Text] [Related]
16. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.
Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O
J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828
[TBL] [Abstract][Full Text] [Related]
17. Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier.
Bauer M; Karch R; Zeitlinger M; Stanek J; Philippe C; Wadsak W; Mitterhauser M; Jäger W; Haslacher H; Müller M; Langer O
J Nucl Med; 2013 Aug; 54(8):1181-7. PubMed ID: 23833270
[TBL] [Abstract][Full Text] [Related]
18. The influence of mass of [11C]-laniquidar and [11C]-N-desmethyl-loperamide on P-glycoprotein blockage at the blood-brain barrier.
Moerman L; Dumolyn C; Boon P; De Vos F
Nucl Med Biol; 2012 Jan; 39(1):121-5. PubMed ID: 21958857
[TBL] [Abstract][Full Text] [Related]
19. A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier.
Wanek T; Kuntner C; Bankstahl JP; Mairinger S; Bankstahl M; Stanek J; Sauberer M; Filip T; Erker T; Müller M; Löscher W; Langer O
J Cereb Blood Flow Metab; 2012 Nov; 32(11):2002-11. PubMed ID: 22828996
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
Sugimoto H; Hirabayashi H; Amano N; Moriwaki T
Drug Metab Dispos; 2013 Apr; 41(4):683-8. PubMed ID: 23340958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
